BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-624@pharmaconomics
DTSTAMP:20260707T003655Z
DTSTART;VALUE=DATE:20260930
DTEND;VALUE=DATE:20261001
SUMMARY:TECX Phase 1 — TX2100 (estimated date)
DESCRIPTION:Phase 1 trial results for TX2100 in Hereditary Hemorrhagic Telangiectasia (HHT) are due ~ Sep 30\, 2026. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1681087/000119312526212069/tecx-ex99_1.htm\n\nTrack it: https://pharmaconomics.com/e/624
URL:https://pharmaconomics.com/e/624
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:TECX catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR